Pay to Marwadi

Company Profile

SEQUENT SCIENTIFIC LTD.

NSE : SEQUENTBSE : 512529ISIN CODE : INE807F01027Industry : Pharmaceuticals & DrugsHouse : Sequent
BSE97.700.65 (+0.67 % )
PREV CLOSE (Rs.) 97.05
OPEN PRICE (Rs.) 97.80
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 92617
TODAY'S LOW / HIGH (Rs.)96.05 99.75
52 WK LOW / HIGH (Rs.)81.4 319
NSE97.95 0.95 (+0.98 % )
PREV CLOSE(Rs.) 97.00
OPEN PRICE (Rs.) 96.80
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 97.95 (1024 )
VOLUME 933626
TODAY'S LOW / HIGH(Rs.) 96.05 99.75
52 WK LOW / HIGH (Rs.)82 319.15

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.51
TTM EPS (Rs.) 0.59
P/E Ratio 164.67
Book Value (Rs.) 42.10
Face Value (Rs.) 2
MCap (Rs. in Mn) 24369.65
Price/Earning (TTM) 99.91
Price/Sales (TTM) 11.10
Price/Book (MRQ) 2.32
PAT Margin (%) 11.95
ROCE (%) 4.45
Incorporation Year : 1985

Management Info :

Kamal K Sharma - Chairman Rajaram Narayanan - Managing Director

Registered Office :

Address : 301, ' Dosti Pinnacle',3rd Floor, Plot No. E7,Road No. 22, Wagle Indl. Estate, Thane (W) ,
Thane,
Maharashtra-400604

Phone : 022 4111 4777

Website : www.sequent.in

Registrar's Details : K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE
NEWS More
26Apr04-26-2022$Sequent Scientific informs about allotment of equity shares under ESOP Sequent Scientific informs a

Sequent Scientific has informed that the Board of Directors of the Company vide a resolution passed by circulation on April 25, 2022, has approved issue and allotment of 10,62,500 Equity Shares of Rs 2 each fully paid to the Employees at an exercise price of Rs 86 per equity share on exercise of the options granted to them under SeQuent ESOP Plan 2020. The said Equity shares shall rank, in all respects with the existing equity shares of the Company. Consequent to the allotment of the aforesaid equity shares, the issued and the paid-up equity share capital of the Company will increase from Rs 49,67,41,990 consisting of 24,83,70,995 Equity Shares of Rs 2 each to Rs 49,88,66,990 consisting of 24,94,33,495 Equity Shares of Rs 2 each. The details as required under the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 are enclosed as Annexure-I.

The above information is a part of company’s filings submitted to BSE.

Sequent Scientific has informed that the Board of Directors of..
26Apr04-26-2022$ Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS Announcement under Regulati
Dear Sir/ Madam, We wish to inform you that the Board of Directors of the Company vide a resolution passed by circulation on April 25, 2022, has approved issueand allotment of 10,62,500 Equity Shares of Rs. 2/- each fully paid to the Employees at an exercise price of Rs. 86/- per equity share on exercise of theoptions granted to them under SeQuent ESOP Plan 2020. The said Equity shares shall rank pari passu, in all respects with the existing equity shares of theCompany. Consequent to the allotment of the aforesaid equity shares, the issued and the paid-up equity share capital of the Company will increase from Rs.49,67,41,990 consisting of 24,83,70,995 Equity Shares of Rs. 2/- each to Rs. 49,88,66,990 consisting of 24,94,33,495 Equity Shares of Rs. 2/- each. Kindlytake the same on your record.
Dear Sir/ Madam, We wish to inform you that the Board of Direc..
18Apr04-18-2022$ Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO) Announcement under Regulati
We wish to inform you that Mr. Tushar Mistry has resigned from the position of Chief Financial Officer of the Company on April 14, 2022, to pursue otherprofessional opportunities. He will continue in his current role till the close of business hours on May 31, 2022. The Board will announce his successor in duecourse. Requisite disclosure required under Regulation 30 of the Listing Regulations read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015, isattached as 'Annexure 1'. We request you to take the above on your record.
We wish to inform you that Mr. Tushar Mistry has resigned from..
11Apr04-11-2022$ Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 Ref Intimation Under Regulation
We wish to inform you that Shareholders on April 09, 2022, through postal ballot approved granting of Employee Stock Options to Mr. Rajaram Narayanan, Managing Director and CEO of the Company, during any one year, equal to or exceeding one percent of the issued capital (excluding warrants and conversions) of the Company at the time of grant of options. Pursuant to the above, 71,00,000 Employee Stock Options consisting of 40,00,000 Class A Options, 22,00,000 Class B Options and 9,00,000 Class C Options granted to Mr. Rajaram Narayanan at an exercise price of Rs. 86/- per equity share under the 'SeQuent ESOP Scheme 2020' will be effective from April 11, 2022. The said options are convertible into equivalent number of equity shares of Rs. 2/- each of the Company, on exercise. The options will vest as per the terms of the 'SeQuent ESOP Scheme 2020'. We request you to take the above on your record.
We wish to inform you that Shareholders on April 09, 2022, thro..
11Apr04-11-2022$ Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 Ref Intimation Under Regulation
We wish to inform you that Shareholders on April 09, 2022, through postal ballot approved granting of Employee Stock Options to Mr. Rajaram Narayanan, Managing Director and CEO of the Company, during any one year, equal to or exceeding one percent of the issued capital (excluding warrants and conversions) of the Company at the time of grant of options. Pursuant to the above, 71,00,000 Employee Stock Options consisting of 40,00,000 Class A Options, 22,00,000 Class B Options and 9,00,000 Class C Options granted to Mr. Rajaram Narayanan at an exercise price of Rs. 86/- per equity share under the 'SeQuent ESOP Scheme 2020' will be effective from April 11, 2022. The said options are convertible into equivalent number of equity shares of Rs. 2/- each of the Company, on exercise. The options will vest as per the terms of the 'SeQuent ESOP Scheme 2020'. We request you to take the above on your record.
We wish to inform you that Shareholders on April 09, 2022, thro..
Financials More
Rs. in Millions
QTR Mar 22 ANNUAL 22
Net Profit66.48147.99
Gross Profit 80.37 156.9
Operating Profit 109.86268.93
Net Sales 636.732196.26
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Astrazeneca Pharma I (BSE)
 2960.30 (8.08%)
M.Cap ( in Cr)
7400.75
Procter&Gamble Healt (BSE)
 4278.25 (1.95%)
M.Cap ( in Cr)
7143.71
Sanofi India (BSE)
 6443.65 (0.95%)
M.Cap ( in Cr)
14910.02
Kilitch Drugs(India) (BSE)
 184.15 (16.48%)
M.Cap ( in Cr)
285.39
Dr. Reddy's Lab (BSE)
 4389.45 (0.54%)
M.Cap ( in Cr)
73058.45
Shareholding Pattern More
PROMOTERS 53.02 %
NON-INSTITUTION 39.11 %
MUTUAL FUNDS/UTI 0.3 %
FI/BANKS/INSURANCE 0 %
GOVERNMENT 0 %
FII 0 %
MF HOLDINGS More
Scheme NameHold(%)
Nippon India Nifty Smal...0.15
F & O Quotes